LeMaitre Vascular (NASDAQ:LMAT) Price Target Lowered to $93.00 at Wells Fargo & Company

LeMaitre Vascular (NASDAQ:LMAT) had its price target reduced by equities researchers at Wells Fargo & Company from $97.00 to $93.00 in a report issued on Friday,Benzinga reports. The brokerage presently has an “equal weight” rating on the medical instruments supplier’s stock. Wells Fargo & Company‘s price objective would suggest a potential upside of 7.12% from the company’s previous close.

Several other research firms have also issued reports on LMAT. Roth Capital reissued a “buy” rating and issued a $108.00 price objective on shares of LeMaitre Vascular in a research report on Wednesday. Weiss Ratings reaffirmed a “buy (b-)” rating on shares of LeMaitre Vascular in a research report on Wednesday, October 8th. Cantor Fitzgerald raised their target price on LeMaitre Vascular from $92.00 to $95.00 and gave the company a “neutral” rating in a report on Wednesday, August 6th. Finally, Barrington Research reissued an “outperform” rating and set a $95.00 price target on shares of LeMaitre Vascular in a research report on Wednesday, October 15th. Four investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat.com, LeMaitre Vascular has an average rating of “Moderate Buy” and an average price target of $100.20.

LeMaitre Vascular Trading Up 1.4%

Shares of LMAT traded up $1.22 during trading hours on Friday, hitting $86.82. The stock had a trading volume of 275,971 shares, compared to its average volume of 182,389. LeMaitre Vascular has a 12-month low of $71.42 and a 12-month high of $109.58. The firm has a market cap of $1.97 billion, a P/E ratio of 42.15, a P/E/G ratio of 2.29 and a beta of 0.77. The company has a debt-to-equity ratio of 0.46, a quick ratio of 11.74 and a current ratio of 13.96. The company’s fifty day simple moving average is $89.75 and its 200 day simple moving average is $87.00.

LeMaitre Vascular (NASDAQ:LMAT) last announced its quarterly earnings results on Thursday, November 6th. The medical instruments supplier reported $0.62 EPS for the quarter, topping the consensus estimate of $0.57 by $0.05. The company had revenue of $61.05 million during the quarter, compared to analyst estimates of $62.18 million. LeMaitre Vascular had a return on equity of 13.67% and a net margin of 20.08%.The firm’s revenue was up 11.4% on a year-over-year basis. During the same period in the prior year, the firm posted $0.49 earnings per share. LeMaitre Vascular has set its FY 2025 guidance at 2.480-2.530 EPS. Q4 2025 guidance at 0.640-0.690 EPS. Equities research analysts forecast that LeMaitre Vascular will post 1.94 EPS for the current fiscal year.

Insider Activity at LeMaitre Vascular

In other LeMaitre Vascular news, Director David B. Roberts sold 10,815 shares of the stock in a transaction that occurred on Monday, August 11th. The stock was sold at an average price of $92.39, for a total transaction of $999,197.85. Following the transaction, the director owned 17,976 shares of the company’s stock, valued at $1,660,802.64. This trade represents a 37.56% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director John A. Roush sold 6,561 shares of the firm’s stock in a transaction on Monday, August 11th. The stock was sold at an average price of $92.55, for a total value of $607,220.55. Following the transaction, the director owned 2,916 shares in the company, valued at $269,875.80. This trade represents a 69.23% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Corporate insiders own 9.50% of the company’s stock.

Institutional Investors Weigh In On LeMaitre Vascular

A number of institutional investors have recently modified their holdings of the business. Advisors Asset Management Inc. lifted its holdings in LeMaitre Vascular by 3.0% in the second quarter. Advisors Asset Management Inc. now owns 4,111 shares of the medical instruments supplier’s stock worth $341,000 after acquiring an additional 118 shares during the last quarter. Johnson Investment Counsel Inc. raised its position in shares of LeMaitre Vascular by 0.5% during the 3rd quarter. Johnson Investment Counsel Inc. now owns 29,792 shares of the medical instruments supplier’s stock worth $2,607,000 after purchasing an additional 153 shares during the period. Federated Hermes Inc. lifted its holdings in shares of LeMaitre Vascular by 0.4% in the 2nd quarter. Federated Hermes Inc. now owns 39,659 shares of the medical instruments supplier’s stock worth $3,294,000 after purchasing an additional 155 shares during the last quarter. Jones Financial Companies Lllp boosted its position in LeMaitre Vascular by 2.2% during the 3rd quarter. Jones Financial Companies Lllp now owns 7,486 shares of the medical instruments supplier’s stock valued at $630,000 after purchasing an additional 158 shares during the period. Finally, Illinois Municipal Retirement Fund grew its stake in LeMaitre Vascular by 1.6% during the 3rd quarter. Illinois Municipal Retirement Fund now owns 11,048 shares of the medical instruments supplier’s stock worth $967,000 after buying an additional 171 shares during the last quarter. Institutional investors own 84.64% of the company’s stock.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.